Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung

Small Cell Lung Carcinoma

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Small Cell Lung Carcinoma

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

Thymic epithelial tumor, Mediastinal Neoplasms, Thymoma

Non-Small Cell Lung Cancer Metastatic

Lung Neoplasms, Small Cell Lung Carcinoma

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Small Cell Lung Carcinoma

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Lung Neoplasms

Lung Neoplasms, Small Cell Lung Carcinoma

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Mesothelioma, Malignant

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Adenocarcinoma of Lung

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Neoplasms, Small Cell Lung Carcinoma

Resectable Stage IIA to IIIB Non-small Cell Lung Cancer

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

Mesothelioma, Malignant, Mesothelioma

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Mesothelioma, Malignant

Carcinoma, Non-Small-Cell Lung

Metastatic Squamous Non-Small Cell Lung Carcinoma

Carcinoma, Non-Small-Cell Lung

Extensive Stage Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Lung Neoplasms, Sarcopenia

Clinical Trials

Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%

MOZART

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment

IMMUNOLIFE2

Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients

XACT-LUNG

Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression

6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors

ANTELOPE

Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

NIRVANA-LUNG

Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment

AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer

Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer

Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC

G360-IIT

Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer

Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC

SPORADIC

A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer

LAG-MAPS

PLANET

Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC

MPDL3280A With Chemoradiation for Lung Cancer

SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC

CRYOMUNE

HyDose

TRIPLEX

An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer

Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study

DREAM3R

Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases

Plasma-Adapted First-Line Pembro In NSCLC

CHIMERA

FLAME

LUNG-IST-127

Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance

Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer

MIGRANT

SACTION 2501

A Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer.

Impact of Fat-free Mass in the Carboplatin Calculated Dose and Chemotherapeutic Toxicity in Patients With Advanced NSCLC